HGH Fragment 176-191 vs Dermorphin
Side-by-side comparison of key properties, dosing, and research.
Fat Loss & Metabolic
HGH Fragment 176-191Recovery & Repair
Dermorphin- Summary
- HGH Fragment 176-191 (also known as AOD-9604) is a stabilized, modified fragment of the human growth hormone molecule corresponding to amino acids 176–191 with an addition of a tyrosine residue at the N-terminus. It retains HGH's fat-burning properties without the anabolic, diabetogenic, or IGF-1-stimulating effects.
- Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
- Half-Life
- ~30 minutes
- Estimated 30-60 minutes (longer than endorphins due to D-Ala)
- Admin Route
- SubQ
- Subcutaneous (research), Intrathecal (research), Intranasal (research)
- Research
- —
- —
- Typical Dose
- 250–500 mcg
- Not established for human use; research doses vary widely
- Frequency
- 1–3 times daily
- Not established
- Key Benefits
- Selective fat burning without anabolic side effects
- Reduces visceral and subcutaneous fat
- No insulin resistance or blood glucose disruption
- Does not stimulate IGF-1
- May support cartilage and bone repair (at higher doses)
- No effect on growth or organ size
- Potent analgesia superior to morphine on a per-weight basis
- May reduce perception of fatigue in high-intensity activity
- Longer-lasting than endogenous opioids due to D-amino acid substitution
- Research tool for mu-opioid receptor pharmacology
- Potential therapeutic application in refractory pain
- Side Effects
- Injection site irritation
- Temporary lethargy
- Headache (rare)
- Nausea (rare)
- High addiction and dependence potential (mu-opioid agonism)
- Respiratory depression at high doses
- Nausea, vomiting, constipation
- Sedation and cognitive impairment
- +2 more
- Stacks With
- —
- —